Sex differences in the pharmacotherapy of neurological patients
Abstract Recent epidemiological studies indicate that neurological disorders are currently the leading cause of disability and the second leading cause of mortality worldwide. In recent decades, considerable progress has been made in understanding the aetiology and treatment of neurological disorder...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | The Egyptian Journal of Neurology, Psychiatry and Neurosurgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41983-025-00990-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328955464613888 |
|---|---|
| author | Lejla Ćorić Željka Petelin Gadže Asja Hodžić Jelena Bošnjak Karlo Papić |
| author_facet | Lejla Ćorić Željka Petelin Gadže Asja Hodžić Jelena Bošnjak Karlo Papić |
| author_sort | Lejla Ćorić |
| collection | DOAJ |
| description | Abstract Recent epidemiological studies indicate that neurological disorders are currently the leading cause of disability and the second leading cause of mortality worldwide. In recent decades, considerable progress has been made in understanding the aetiology and treatment of neurological disorders. To achieve an adequate therapeutic effect and reduce the possibility of unwanted reactions, it is necessary to gain a thorough understanding of the factors that influence pharmacokinetics and pharmacodynamics. For many years, females have not been sufficiently included in clinical studies of drugs. The reasons are primarily related to the fear of adverse effects of the tested drugs during pregnancy and breastfeeding. However, at the beginning of the current millennium, females began to be increasingly included in clinical trials in response to recommendations from the United States Food and Drug Administration (FDA). Therefore, knowledge of sex differences in the pharmacokinetics and pharmacodynamics of drugs is increasing. Nevertheless, there are currently no specific recommendations regarding the dosage differentiation of most drugs between females and males. This article aims to summarize current knowledge on current knowledge on sex differences in the pharmacokinetics, efficacy, and safety of drugs commonly used to treat neurological patients to achieve a personalized approach. In the future, attention should be devoted to evaluating differences in the pharmacokinetics of drugs under development to optimize their therapeutic effects and reduce the number of adverse reactions in both sexes. |
| format | Article |
| id | doaj-art-bae65ef933e540079fec38e0225171c9 |
| institution | Kabale University |
| issn | 1687-8329 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Neurology, Psychiatry and Neurosurgery |
| spelling | doaj-art-bae65ef933e540079fec38e0225171c92025-08-20T03:47:24ZengSpringerOpenThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery1687-83292025-06-0161111010.1186/s41983-025-00990-5Sex differences in the pharmacotherapy of neurological patientsLejla Ćorić0Željka Petelin Gadže1Asja Hodžić2Jelena Bošnjak3Karlo Papić4University Hospital DubravaUniversity Hospital Centre Zagreb and School of Medicine, University of ZagrebUniversity Clinical Hospital MostarCommunity Health Center ZagrebCommunity Health Center ZagrebAbstract Recent epidemiological studies indicate that neurological disorders are currently the leading cause of disability and the second leading cause of mortality worldwide. In recent decades, considerable progress has been made in understanding the aetiology and treatment of neurological disorders. To achieve an adequate therapeutic effect and reduce the possibility of unwanted reactions, it is necessary to gain a thorough understanding of the factors that influence pharmacokinetics and pharmacodynamics. For many years, females have not been sufficiently included in clinical studies of drugs. The reasons are primarily related to the fear of adverse effects of the tested drugs during pregnancy and breastfeeding. However, at the beginning of the current millennium, females began to be increasingly included in clinical trials in response to recommendations from the United States Food and Drug Administration (FDA). Therefore, knowledge of sex differences in the pharmacokinetics and pharmacodynamics of drugs is increasing. Nevertheless, there are currently no specific recommendations regarding the dosage differentiation of most drugs between females and males. This article aims to summarize current knowledge on current knowledge on sex differences in the pharmacokinetics, efficacy, and safety of drugs commonly used to treat neurological patients to achieve a personalized approach. In the future, attention should be devoted to evaluating differences in the pharmacokinetics of drugs under development to optimize their therapeutic effects and reduce the number of adverse reactions in both sexes.https://doi.org/10.1186/s41983-025-00990-5SexGenderPharmacokineticsPharmacodynamicsNeurological disorders |
| spellingShingle | Lejla Ćorić Željka Petelin Gadže Asja Hodžić Jelena Bošnjak Karlo Papić Sex differences in the pharmacotherapy of neurological patients The Egyptian Journal of Neurology, Psychiatry and Neurosurgery Sex Gender Pharmacokinetics Pharmacodynamics Neurological disorders |
| title | Sex differences in the pharmacotherapy of neurological patients |
| title_full | Sex differences in the pharmacotherapy of neurological patients |
| title_fullStr | Sex differences in the pharmacotherapy of neurological patients |
| title_full_unstemmed | Sex differences in the pharmacotherapy of neurological patients |
| title_short | Sex differences in the pharmacotherapy of neurological patients |
| title_sort | sex differences in the pharmacotherapy of neurological patients |
| topic | Sex Gender Pharmacokinetics Pharmacodynamics Neurological disorders |
| url | https://doi.org/10.1186/s41983-025-00990-5 |
| work_keys_str_mv | AT lejlacoric sexdifferencesinthepharmacotherapyofneurologicalpatients AT zeljkapetelingadze sexdifferencesinthepharmacotherapyofneurologicalpatients AT asjahodzic sexdifferencesinthepharmacotherapyofneurologicalpatients AT jelenabosnjak sexdifferencesinthepharmacotherapyofneurologicalpatients AT karlopapic sexdifferencesinthepharmacotherapyofneurologicalpatients |